Toward a more parsimonious assessment of neurocognition in schizophrenia: A 10-minute assessment tool

Journal of Psychiatric Research

Volumn 52, Issue 1, 2014, Pages 50-56

  Fervaha, Gagan ^a,b   Agid, Ofer ^a,c   Foussias, George ^a,b,c   Remington, Gary ^a,b,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Brief neurocognitive assessment; Cognition; Neuropsychological testing; Psychopathology; Psychosocial functioning; Schizophrenia

Indexed keywords

ADULT; ARTICLE; BRIEF NEUROCOGNITIVE ASSESSMENT; CLINICAL ASSESSMENT TOOL; COGNITION; DISEASE SEVERITY; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROCOGNITION; NEUROPSYCHOLOGICAL BATTERY; NEUROPSYCHOLOGICAL TEST; PREDICTIVE VALUE; PRIORITY JOURNAL; SCHIZOPHRENIA; TEST RETEST RELIABILITY; VALIDITY; WORKING MEMORY; ADOLESCENT; AGED; COGNITION DISORDERS; COMPLICATION; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; REGRESSION ANALYSIS; REPRODUCIBILITY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

EID: 84895894610     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2014.01.009     Document Type: Article

References (44)

1. Addington D., Addington J., Schissel B. Adepression rating scale for schizophrenics. Schizophr Res 1990, 3:247-251.
2. Davidson M., Galderisi S., Weiser M., Werbeloff N., Fleischhacker W.W., Keefe R.S., et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 2009, 166:675-682.
3. Dickinson D., Gold J.M. Less unique variance than meets the eye: overlap among traditional neuropsychological dimensions in schizophrenia. Schizophr Bull 2008, 34:423-434.
4. Dickinson D., Iannone V.N., Wilk C.M., Gold J.M. General and specific cognitive deficits in schizophrenia. Biol Psychiatry 2004, 55:826-833.
5. Dickinson D., Ragland J.D., Calkins M.E., Gold J.M., Gur R.C. Acomparison of cognitive structure in schizophrenia patients and healthy controls using confirmatory factor analysis. Schizophr Res 2006, 85:20-29.
6. Dickinson D., Ragland J.D., Gold J.M., Gur R.C. General and specific cognitive deficits in schizophrenia: Goliath defeats David?. Biol Psychiatry 2008, 64:823-827.
7. Dickinson D., Ramsey M.E., Gold J.M. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry 2007, 64:532-542.
8. Efron B., Tibshirani R. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Statist Sci 1986, 1:54-75.
9. First M.B. User's guide for the Structured clinical interview for DSM-IV axis I disorders SCID-I: clinician version 1997, Amer Psychiatric Pub Inc, Washington, DC.
10. Freedman R. Schizophrenia. New Engl J Med 2003, 349:1738-1749.
11. Gold J.M., Queern C., Iannone V.N., Buchanan R.W. Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia I: sensitivity, reliability, and validity. Am J Psychiatry 1999, 156:1944-1950.
12. Gonzalez-Blanch C., Perez-Iglesias R., Rodriguez-Sanchez J.M., Pardo-Garcia G., Martinez-Garcia O., Vazquez-Barquero J.L., et al. Adigit symbol coding task as a screening instrument for cognitive impairment in first-episode psychosis. Arch Clin Neuropsychol 2011, 26:48-58.
13. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry 1996, 153:321-330.
14. Green M.F., Kern R.S., Braff D.L., Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff". Schizophr Bull 2000, 26:119-136.
15. Green M.F., Nuechterlein K.H., Gold J.M., Barch D.M., Cohen J., Essock S., et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 2004, 56:301-307.
16. Guy W. ECDEU Assessment manual for psychopharmacology-Revised 1976, National Institute of Health, Department of Health, Education, and Welfare, Rockville, MD.
17. Harvey P.D., Keefe R.S. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001, 158:176-184.
18. Harvey P.D., Keefe R.S., Patterson T.L., Heaton R.K., Bowie C.R. Abbreviated neuropsychological assessment in schizophrenia: prediction of different aspects of outcome. JClin Exp Neuropsychol 2009, 31:462-471.
19. Heinrichs D.W., Hanlon T.E., Carpenter W.T. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984, 10:388-398.
20. Hill S.K., Sweeney J.A., Hamer R.M., Keefe R.S., Perkins D.O., Gu H., et al. Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia. JInt Neuropsychological Soc 2008, 14:209-221.
21. Hobart M.P., Goldberg R., Bartko J.J., Gold J.M. Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia, II: Convergent/discriminant validity and diagnostic group comparisons. Am J Psychiatry 1999, 156:1951-1957.
22. Hurford I.M., Marder S.R., Keefe R.S., Reise S.P., Bilder R.M. Abrief cognitive assessment tool for schizophrenia: construction of a tool for clinicians. Schizophr Bull 2011, 37:538-545.
23. Johnson M.K., McMahon R.P., Robinson B.M., Harvey A.N., Hahn B., Leonard C.J., et al. The relationship between working memory capacity and broad measures of cognitive ability in healthy adults and people with schizophrenia. Neuropsychology 2013, 27:220-229.
24. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
25. Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007, 64:633-647.
26. Keefe R.S., Bilder R.M., Harvey P.D., Davis S.M., Palmer B.W., Gold J.M., et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 2006, 31:2033-2046.
27. Keefe R.S., Buchanan R.W., Marder S.R., Schooler N.R., Dugar A., Zivkov M., et al. Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?. Schizophr Bull 2013, 39:417-435.
28. Keefe R.S., Goldberg T.E., Harvey P.D., Gold J.M., Poe M.P., Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 2004, 68:283-297.
29. Keefe R.S., Mohs R.C., Bilder R.M., Harvey P.D., Green M.F., Meltzer H.Y., et al. Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophr Bull 2003, 29:45-55.
30. Keefe R.S., Poe M., Walker T.M., Harvey P.D. The relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to functional capacity and real-world functional outcome. JClin Exp Neuropsychol 2006, 28:260-269.
31. Keefe R.S., Sweeney J.A., Gu H., Hamer R.M., Perkins D.O., McEvoy J.P., et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007, 164:1061-1071.
32. Kirkpatrick B., Fenton W.S., Carpenter W.T., Marder S.R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006, 32:214-219.
33. Knowles E.E., David A.S., Reichenberg A. Processing speed deficits in schizophrenia: reexamining the evidence. Am J Psychiatry 2010, 167:828-835.
34. Lezak M.D. Neuropsychological assessment 2004, Oxford University Press, USA. 4th ed.
35. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 2005, 353:1209-1223.
36. Milev P., Ho B.C., Arndt S., Andreasen N.C. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 2005, 162:495-506.
37. Mohamed S., Paulsen J.S., O'Leary D., Arndt S., Andreasen N. Generalized cognitive deficits in schizophrenia: a study of first-episode patients. Arch Gen Psychiatry 1999, 56:749-754.
38. Mohamed S., Rosenheck R., Swartz M., Stroup S., Lieberman J.A., Keefe R.S. Relationship of cognition and psychopathology to functional impairment in schizophrenia. Am J Psychiatry 2008, 165:978-987.
39. Nuechterlein K.H., Green M.F., Kern R.S., Baade L.E., Barch D.M., Cohen J.D., et al. The MATRICS Consensus Cognitive Battery, part 1: Test selection, reliability, and validity. Am J Psychiatry 2008, 165:203-213.
40. Perlick D.A., Rosenheck R.A., Kaczynski R., Bingham S., Collins J. Association of symptomatology and cognitive deficits to functional capacity in schizophrenia. Schizophr Res 2008, 99:192-199.
41. Rodriguez-Sanchez J.M., Crespo-Facorro B., Gonzalez-Blanch C., Perez-Iglesias R., Vazquez-Barquero J.L. Cognitive dysfunction in first-episode psychosis: the processing speed hypothesis. Br J Psychiatry Suppl 2007, 51:s107-110.
42. Saeedi H., Remington G., Christensen B.K. Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood. Schizophr Res 2006, 85:222-231.
43. Stroup T.S., McEvoy J.P., Swartz M.S., Byerly M.J., Glick I.D., Canive J.M., et al. The National Institute of mental health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003, 29:15-31.
44. Velligan D.I., DiCocco M., Bow-Thomas C.C., Cadle C., Glahn D.C., Miller A.L., et al. Abrief cognitive assessment for use with schizophrenia patients in community clinics. Schizophr Res 2004, 71:273-283.